Benishin C G
Department of Physiology, Faculty of Medicine, University of Alberta, Edmonton, Canada.
Neurochem Int. 1992 Jul;21(1):1-5. doi: 10.1016/0197-0186(92)90061-u.
The ginsenoside Rb1 has previously been reported to improve memory deficits induced by anticholinergic drug treatment, and to facilitate acetylcholine (Ach) release from rat brain hippocampal slices. The increase in ACh release was not associated with an increase in calcium uptake into nerve terminals, but was associated with an increase in uptake of the precursor choline. In the present studies, analysis of choline uptake kinetics indicated that Rb1 increased the maximum velocity of choline uptake, while the affinity of the choline uptake carrier for choline (Km) was not significantly altered. Acute treatment with Rb1 did not alter the number of [3H]hemicholinium-3 (HC-3) binding sites in any of three cholinergic brain regions examined, suggesting that the increase in the maximum velocity of choline uptake was not associated with an increase in the number of choline carriers. However, chronic (3 day) administration of Rb1 did increase the number of choline uptake sites in the hippocampus, and to a lesser extent in the cortex.
此前有报道称,人参皂苷Rb1可改善抗胆碱能药物治疗引起的记忆缺陷,并促进乙酰胆碱(Ach)从大鼠脑海马切片中释放。Ach释放的增加与神经末梢钙摄取的增加无关,而是与前体胆碱摄取的增加有关。在本研究中,胆碱摄取动力学分析表明,Rb1提高了胆碱摄取的最大速度,而胆碱摄取载体对胆碱的亲和力(Km)没有显著改变。用Rb1进行急性处理,在所检测的三个胆碱能脑区中,均未改变[3H]半胱氨酸-3(HC-3)结合位点的数量,这表明胆碱摄取最大速度的增加与胆碱载体数量的增加无关。然而,长期(3天)给予Rb1确实增加了海马体中胆碱摄取位点的数量,在皮质中的增加程度较小。